Lucid Diagnostics Inc. LUCD R2KPHARMA
Company Overview
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Why Investors Should Care
Revenue has grown at a 75.1% CAGR over the past five years.
Recent Developments
- Dec 2025 Revenue of $4.71M (+8.3% YoY); net profit $-58.01M.
- Trailing 12 Months Year-on-year growth — revenue +51.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 75.1%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 75.15% |
| 1 Year: | 51.70% |
Stock Price Performance
| 1 Year: | -4.18% |
| 6 Months: | -32.86% |
| 3 Months: | -2.79% |
| 1 Month: | -1.36% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.70 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 75.1% over 5 years.
CONS
- Trading 36.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LUCD Lucid Diagnostics Inc. R2KPHARMA | 0.94 | -2.76 | $179.33M | 0.00% | - | - | 75.15% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 189.00K | - | 76.00K | 446.00K | 159.00K | 783.00K | 1.00M | 976.00K | 1.17M | 828.00K | 1.16M | 1.21M | - |
| Gross Profit | - | - | - | 200.00K | -180.00K | - | 76.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | -2.02M | -3.65M | -6.02M | -6.51M | -12.27M | -14.63M | -14.38M | -14.32M | -11.58M | -11.13M | -10.79M | -11.19M | -11.69M | -12.49M | -11.38M | -11.76M | -12.11M |
| Net Income | -2.02M | -3.65M | -6.16M | -6.96M | -12.27M | -14.62M | -14.35M | -16.25M | -11.38M | -14.21M | -10.61M | -11.01M | -12.37M | -26.91M | -4.44M | -10.40M | -13.91M |
| Diluted EPS | - | - | - | - | - | -0.41 | -0.39 | -0.40 | -0.27 | -0.34 | -0.40 | -0.23 | -0.25 | -0.52 | -0.08 | -0.10 | - |
| R&D Expense | 1.22M | 1.75M | 1.87M | 2.19M | 2.88M | 3.44M | 2.70M | 1.89M | 1.83M | 1.61M | 1.50M | 1.37M | 1.67M | 1.43M | 1.25M | 1.27M | 1.21M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 500.00K | 377.00K | 2.43M | 4.35M | 4.71M |
| Gross Profit | - | 500.00K | 377.00K | - | - | - |
| Operating Income | -8.28M | -27.42M | -56.25M | -48.48M | -46.05M | -49.64M |
| Net Income | -8.28M | -28.08M | -56.17M | -52.67M | -45.53M | -58.01M |
| Diluted EPS | - | - | -1.55 | -1.26 | -1.05 | - |
| R&D Expense | 5.44M | 9.30M | 11.26M | 7.25M | 5.99M | 5.68M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.19M | 59.00M | 32.51M | 27.27M | 30.71M | 40.45M |
| Total Equity | -5.31M | -13.52M | 54.74M | 23.05M | -2.31M | 5.39M | 10.94M |
| Cash & Equivalents | - | - | 53.66M | 22.47M | 18.90M | 22.36M | - |
| Total Liabilities | - | 15.71M | 4.26M | 9.46M | 29.58M | 25.32M | 29.51M |
| Current Liabilities | - | - | 4.26M | 8.43M | 29.38M | 23.52M | 28.58M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -5.63M | - | -29.68M | -32.82M | -44.14M | -46.48M |
| Investing Cash Flow | - | - | -4.11M | -221.00K | -646.00K | -197.00K |
| Financing Cash Flow | 5.58M | - | 2.61M | 29.46M | 48.25M | 59.03M |
| Capital Expenditure | - | - | -908.00K | -221.00K | -646.00K | -197.00K |
| Free Cash Flow | - | - | -30.59M | -33.04M | -44.79M | -46.68M |
| Net Change in Cash | - | - | -31.18M | -3.58M | 3.46M | 12.35M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | 100.0% | 100.0% | - | - | - |
| Operating Margin % | - | -5,483.8% | -14,920.7% | -1,996.8% | -1,059.6% | -1,054.8% |
| Net Margin % | - | -5,615.6% | -14,899.5% | -2,169.1% | -1,047.6% | -1,232.7% |
| ROE % | 61.3% | -51.3% | -243.7% | 2,278.9% | -844.5% | -530.4% |
| ROCE % | - | -50.1% | -233.6% | 2,295.5% | -640.4% | -418.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Alyeska Investment Group, L.p. | 4.36% | 8.86M | $8.78M |
| 2 | Blackrock Inc. | 4.12% | 8.37M | $8.30M |
| 3 | Vanguard Capital Management LLC | 3.23% | 6.56M | $6.50M |
| 4 | Two Seas Capital Lp | 2.95% | 6.00M | $5.95M |
| 5 | Masters Capital Management, LLC | 1.97% | 4.00M | $3.97M |
| 6 | Aberdeen Group plc | 1.88% | 3.82M | $3.79M |
| 7 | Geode Capital Management, LLC | 1.86% | 3.79M | $3.76M |
| 8 | State Street Corporation | 1.20% | 2.44M | $2.42M |
| 9 | First Manhattan Co. LLC | 1.08% | 2.19M | $2.17M |
| 10 | Wells Fargo & Company | 1.02% | 2.07M | $2.05M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LUCD
Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results - PR Newswire
<a href="https://news.google.com/rss/articles/CBMi4gFBVV95cUxNN0tQRG9SRExmRHR2R002T2NvS1lGbEYyVFpwOWxFbFVzbk1vS1UwbWZxNU82eGIzbDRrMFBqM18wQWxDdDlKMk9JLVpFUTVQdnZwR0N3WHNKX0U3Ny1IZkNsdnZiSVB2MGtGd09JSkJqVWY1d2lQN1I1NHM4TlJlNHNVRVUwekNCaTNDN3…
$LUCD stock is down 12% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxPRFJWYU5UYlB1TGpFQ3Eyc2x2YWE3WktjaGlrMXc2bnRmbjZxV0xQZDY0SExmNkNVTjlXeDJRZ21sVXlhYWFtS0ZKanNjeTgzTFlHZ3VMSEU4bnZsZ2VUSnRaVFoxT3FMV18telZSMF85TTFvdXk2ay1RNmVqRUV6cmFJdk9janBBcGhkc1…
Lucid Diagnostics Inc. (LUCD) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxQU1RLZjl5UWlhODVfUWtTZ0syYkFSNktaZFZtdllBZlA2MkJXUUVQNEpCaUJGLWdGYlVUUElydVFialYzNTdVVE53MWRnWTc1UkhtMXRFTk9NREtraUFFeWZMR2NYTDAtbkw1WnhLTGl0c2x6N1c5elVLa0dGaGJ3aUJKMTIyaXhvalozdH…
LUCD Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5KTVhDZmlsTnZISzhuS2N4V0lpdEQ0c0lHMDBSeVhNMDdCN1kzZVFDVVp4M04wWGcyakt1aG5WYmxOZVFSaG0tOXRkYjR2TzlDN1ZtdjBJejcyOTZyWU1sa0VrYTJEMHhnQmx5ektoV251RlNFc21melZ3?oc=5" target="_blank">LUC…
Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, LUCD Stock News, LUCD Share Price & Updates - Kalkine
<a href="https://news.google.com/rss/articles/CBMiVkFVX3lxTE9paFpWWldfcDc2UGtVUWF5d0g4S3hwelZudlBKMjN5aDhsS0xQMFpjZnI4S2RSVl9kMmRuY2V6YmhxNS0ycTdySzZhbGtFQk5XenFoZ1d3?oc=5" target="_blank">Lucid Diagnostics Inc (NASDAQ: LUCD) Share Price, L…
Lucid Stock Price Forecast. Should You Buy LCID? - StockInvest.us
<a href="https://news.google.com/rss/articles/CBMiSEFVX3lxTE1ySFNjQzh2Z2N3Z0xfNFlWdDlDQlhPTG9Halc3ejFfdkVGQUxQZ3Y1RG54UzRNWkliTWRfdWxVbEoxTkhaTlEyUQ?oc=5" target="_blank">Lucid Stock Price Forecast. Should You Buy LCID?</a> <font…
LUCD — Frequently Asked Questions
What is the current share price of Lucid Diagnostics Inc. (LUCD)?
As of 2026-09-07 16:24 PDT, Lucid Diagnostics Inc. (LUCD) trades at $0.94 on NasdaqCM. Its 52-week range is $0.87 to $1.47.
What is the market capitalisation of LUCD?
Lucid Diagnostics Inc. (LUCD) has a market capitalisation of $179.33M on NasdaqCM.
What is the P/E ratio of LUCD?
LUCD trades at a trailing price-to-earnings (P/E) ratio of -2.76. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is -26.14.
Is LUCD a good stock to buy?
This page provides a data-driven analysis of Lucid Diagnostics Inc. (LUCD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.